Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells
Duke University · Duke Medical Center
Abstract
In this study, we investigated whether elimination of CD4+/CD25+ Tregs using the recombinant IL-2 diphtheria toxin conjugate DAB(389)IL-2 (also known as denileukin diftitox and ONTAK) is capable of enhancing the immunostimulatory efficacy of tumor RNA-transfected DC vaccines. We show that DAB(389)IL-2 is capable of selectively eliminating CD25-expressing Tregs from the PBMCs of cancer patients without inducing toxicity on other cellular subsets with intermediate or low expression of CD25. DAB(389)IL-2-mediated Treg depletion resulted in enhanced stimulation of proliferative and cytotoxic T cell responses in vitro but only when DAB(389)IL-2 was omitted during T cell priming. DAB(389)IL-2 significantly reduced…
Citation impact
- FWCI
- 48.60
- Percentile
- 100%
- References
- 33
Authors
1Topics & keywords
- IL-2 receptor
- Immune system
- Immunology
- Cytotoxic T cell
- T cell
- Cancer research
- Regulatory T cell
- Peripheral blood mononuclear cell
- Good health and well-being